Background/Aim: Marginal or decreased amniotic fluid volume by ultrasound estimate and fetal growth restriction have been shown to be significantly associated with perinatal mortality. The association of fetal growth restriction and precisely measured amniotic fluid volume is unknown. The purpose of this study was to determine if adverse pregnancy outcomes are more likely in pregnancies complicated by small-for-gestational-age (SGA) neonates and dye-determined oligohydramnios. Methods: Admissions to neonatal intensive care unit (NICU) and other pregnancy outcomes were analyzed in parturients with known amniotic fluid volume, calculated by the dye-dilution technique. The pregnancy outcomes of those with oligohydramnios and SGA were compared with pregnancies complicated by just one of these two conditions and pregnancies with normal fluid and birth weight. Results: Of 202 patients, oligohydramnios was present in 26% (53), SGA in 15% (30) and both conditions in (5%) (11). Logistic regression, controlling for gestational age, demonstrated that the combination of oligohydramnios and SGA, compared to normal growth and fluid strongly predicted NICU admission (OR 11.1; 95% CI 2.1–59.2) but not other complications. (OR 4.8; 95% CI 0.3–62.9). Conclu sions: SGA with oligohydramnios significantly increases the likelihood of a NICU admission, but not other morbidity.

Mandruzzato G, Antsaklis A, Botet F, Chervenak FA, Figueras F, Grunebaum A, Puerto B, Skupski D, Stanojevic M, WAPM: Intrauterine restriction (IUGR). J Perinat Med 2008;36:277–281.
Simpson GF, Creasy RK: Obstetric management of the growth retarded baby. Clin Obstet Gynecol 1984;150:245–249.
Chamberlain PF, Manning FA, Morrison I, Harman CR, Lange IR: Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcomes. Am J Obstet Gynecol 1984;150:245–249.
American College of Obstetricians and Gynecologists: Intrauterine growth restriction. ACOG Practice Bulletin No. 12. Washington, ACOG, 2000.
American College of Obstetricians and Gynecologists: Ultrasonography in pregnancy. ACOG Practice Bulletin No. 58. Washington, ACOG, 2004.
Craigo SD, Beach ML, Harvey-Wilkes KB, D’Alton ME: Ultrasound predictors of neonatal outcome in intrauterine growth restriction. Am J Perinatol 1996;13:467–471.
Lin CC, Sheikh Z, Lopata R: The association between oligohydramnios and intrauterine growth retardation. Obstet Gynecol 1990;76:1100–1104.
Chauhan SP, Taylor M, Shields D, Parker D, Scardo JA, Magann EF: Intrauterine growth restriction and oligohydramnios among high-risk patients. Am J Perinatol 2007;24:215–221.
Magann EF, Nolan TE, Hess LW, Martin RW, Whitworth NS, Morrison JC: Measurement of amniotic fluid volume: accuracy of ultrasonography techniques. Am J Obstet Gynecol 1992;167:1533–1537.
Dildy GA, Lira N, Moise KJ Jr, Riddle GD, Deter RL: Amniotic fluid volume assessment: comparison of ultrasound estimates versus direct measurements with a dye-dilution technique in human pregnancy. Am J Obstet Gynecol 1992;167:986–994.
Horsager R, Nathan L, Leveno KJ: Correlation of measured amniotic fluid volume and sonographic predictions of oligohydramnios. Obstet Gynecol 1994;83:955–958.
Magann EF, Morton ML, Nolan TE, Martin JN Jr, Whitworth NS, Morrison JC: Comparative efficacy of two sonographic measurements for the detection of aberrations in the amniotic fluid volume and the effect of amniotic fluid volume on pregnancy outcome. Obstet Gynecol 1994;83:959–962.
Chauhan SP, Magann EF, Morrison JC, Whitworth NS, Hendrix NW, Devoe LD: Ultrasound assessment of amniotic fluid does not reflect actual amniotic fluid volume. Am J Obstet Gynecol 1997;177:291–296.
Charles D, Jacoby DE: Preliminary data on the use of sodium amniohippurate to determine amniotic fluid volume. AM J Obstet Gynecol 1966;95:266–269.
Magann EF, Whitworth NS, Files JC, Terrone DA, Chauhan SP, Morrison JC: Dye-dilution techniques using amniohippurate sodium: do they accurately reflect amniotic fluid volume? J Matern Fetal Neonatal Med 2002;11:167–170.
Manning FA, Morrison I, Large IR, Harman CR, Chamberlain PF: Fetal assessment based on fetal biophysical profile scoring: experience in 12,620 referred high risk pregnancies. Am J Obstet Gynecol 1985;151:343–350.
Magann EF, Bass JD, Chauhan SP, Young RA, Whitworth NS, Morrison JC: Amniotic fluid volume in normal singleton pregnancies. Obstet Gynecol;90:524–528.
Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M: A United States national reference for fetal growth. Obstet Gynecol 1996;87:163–168.
Casey BM, McIntire DD, Bloom SL, Lucas MJ, Santos R, Twickler DM, Ramus RM, Leveno KJ: Pregnancy outcome after antepartum diagnosis of oligohydramnios at or near 34 weeks’ gestation. Am J Obstet Gynecol 2000;182:909–912.
Magann EF, Chauhan SP, Kinsella MJ, McNamara MF, Whitworth NS, Morrison JC: Antenatal testing among 1001 patients at high risk: the role of ultrasonographic estimate of amniotic fluid volume. Am J Obstet Gynecol 1999;180:1330–1336.
Chauhan SP, Hendrix NW, Morrison JC, Magann EF, Devoe LD: Intrapartum oligohydramnios does not predict adverse peripartum outcome among high-risk parturients. Am J Obstet Gynecol 1997;176:1130–1136.
Chauhan SP, Hendirx NW, Magann EF, Morrison JC, Scardo JA, Berghella V: A review of songraphic estimate of fetal weight: vagaries of accuracy. J Matern Fetal Neonatal Med 2005;18:211–220.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.